Theravance Biopharma TBPH Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $17.7M+15.0% | $45.89M+145% | $19.99M+18.5% | $26.2M+83.7% | $15.39M+6.1% | ||
| $5.83M-49.1% | $7.36M-22.1% | $8.11M-12.5% | $10.49M+5.4% | $11.45M+27.7% | ||
| $17.72M-3.5% | $18.52M+0.1% | $18.33M+8.6% | $18.43M+8.1% | $18.37M+9.7% | ||
| $27.18M-8.9% | $25.88M-7.4% | $26.45M-4.5% | $28.92M-3.5% | $29.82M+16.0% | ||
| $27.18M-8.9% | $25.88M-7.4% | $26.45M-4.5% | $28.92M-3.5% | $29.82M+16.0% | ||
| -$9.48M+34.3% | $20.01M+318% | -$6.46M+40.4% | -$2.73M+82.6% | -$14.43M-28.8% | ||
| -53.6%+40.2pp | 43.6%+92.7pp | -32.3%+32.0pp | -10.4%+99.8pp | -93.8%-16.5pp | ||
| —— | $582K-9.5% | $573K-9.0% | $663K+3.0% | $643K+2.2% | ||
| $3.01M+221% | $3.64M+303% | $4.14M+193% | $1.46M+29.2% | $939K-34.5% | ||
| -$6.47M+54.2% | $73.07M+917% | -$2.89M+71.3% | $73.21M+581% | -$14.14M-35.9% | ||
| -$1.54M-175% | $12.04M+82.8% | -$6.5M-346% | $18.37M+1,305% | -$559K-144% | ||
| -$4.93M+63.7% | $61.02M+493% | $3.62M+128% | $54.84M+432% | -$13.58M-16.4% | ||
| -27.9%+60.4pp | 133%+216pp | 18.1%+93.4pp | 209.3%+325pp | -88.2%-7.8pp | ||
| -$0.10+63.0% | $1.15+471% | $0.07+127% | $1.08+418% | -$0.27-12.5% | ||
| -$0.10+63.0% | $1.20+487% | $0.07+127% | $1.09+421% | -$0.27-12.5% | ||
| 51.3M+3.2% | 51.5M+5.4% | 51.9M+5.9% | 50.7M+4.1% | 49.7M+2.9% | ||
| 51.3M+3.2% | 50.3M+3.0% | 50.5M+3.0% | 50.2M+2.9% | 49.7M+2.9% | ||
| $3.63M— | —— | —— | —— | —— | ||
| —— | $50M— | —— | —— | —— | ||
| $3.01M+221% | $3.64M+303% | $4.14M+193% | $1.46M+29.2% | $939K-34.5% | ||
| $17.7M+15.0% | $45.89M+145% | $19.99M+18.5% | $26.2M+83.7% | $15.39M+6.1% | ||
| -$9.48M+34.3% | $20.01M+318% | -$6.46M+40.4% | -$2.73M+82.6% | -$14.43M-28.8% | ||
| -$9.1M+35.1% | $20.41M+333% | -$6.05M+41.9% | -$2.32M+84.8% | -$14.02M-30.1% | ||
| -$9.1M+35.1% | $20.41M+333% | -$6.05M+41.9% | -$2.32M+84.8% | -$14.02M-30.1% | ||
| -51.4%+39.7pp | 44.5%+91.3pp | -30.3%+31.4pp | -8.8%+98.3pp | -91.1%-16.8pp | ||
| -$9.48M+34.3% | $20.01M+318% | -$6.46M+40.4% | -$2.73M+82.6% | -$14.43M-28.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Theravance Biopharma's revenue?
- Theravance Biopharma (TBPH) generated $109.8M in revenue over the trailing twelve months, up 68.2% year over year.
- Is Theravance Biopharma profitable?
- Theravance Biopharma reported $114.5M in net income over the trailing twelve months, a 104.3% net margin.
- What are Theravance Biopharma's profit margins?
- Gross margin is 60.8% and operating margin is 1.2%, with a 104.3% net margin.
- What is Theravance Biopharma's earnings per share?
- Theravance Biopharma's diluted EPS over the trailing twelve months is $2.20.
- Where does Theravance Biopharma's income statement data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
